Cipla gets EUA from DCGI; to market Molnupiravir for mild-to-moderate COVID-19 treatment

Cipla gets EUA from DCGI; to market Molnupiravir for mild-to-moderate COVID-19 treatment

AgenciesUpdated: Tuesday, December 28, 2021, 03:15 PM IST
article-image
The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu./ Representational image | Photo: Cipla

Drug major Cipla on Tuesday said it has received emergency use authorisation (EUA) permission from the Drug Controller General of India (DCGI) to launch antiviral drug Molnupiravir in the country to treat mild-to-moderate COVID-19.

The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu.

''This launch is yet another step in our endeavour to enable access to all treatments in COVID-19 care. We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients,'' Cipla MD and Global CEO Umang Vohra said in a statement.

Earlier during the year, Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries (LMICs).

The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies.

Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.

Molnupiravir inhibits the replication of multiple RNA viruses including SARS-CoV-2.

Cipla said it will soon make Cipmolnu 200mg capsules available at all leading pharmacies and COVID-19 treatment centers across the country.

The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India, it added.

(With inputs from PTI)

RECENT STORIES

Donald Trump Supports Tough Russia Sanctions Bill, India Faces Possible 500% Tariff Risk

Donald Trump Supports Tough Russia Sanctions Bill, India Faces Possible 500% Tariff Risk

Microsoft Shuts Pakistan Operations After 25 Years, Former Country Head Reflects On Exit

Microsoft Shuts Pakistan Operations After 25 Years, Former Country Head Reflects On Exit

India Not On Latest US Tariff List As Donald Trump Sends Letters To 20 Nations Amid Ongoing Trade...

India Not On Latest US Tariff List As Donald Trump Sends Letters To 20 Nations Amid Ongoing Trade...

Puravankara Expands Bengaluru Footprint, New East Bengaluru Project With ₹1,000 Crore GDV

Puravankara Expands Bengaluru Footprint, New East Bengaluru Project With ₹1,000 Crore GDV

Sensex Today: Markets Open Lower, Investors Cautious Ahead Of TCS Results

Sensex Today: Markets Open Lower, Investors Cautious Ahead Of TCS Results